The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1098
February 19, 2001
View Complete Issue         Table of Contents 2019 
Synagis Revisited
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Synagis Revisited
February 19, 2001 (Issue: 1098)
Palivizumab (Synagis - MedImmune), an injectable monoclonal antibody, has been marketed in the USA since 1999 for prevention of respiratory syncytial virus (RSV) disease in high-risk infants and children.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Synagis Revisited
Article code: 1098a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.